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Abstract
Background: Hand-assisted laparoscopic living donor nephrectomy (HALDN) using a periumbilical or Pfannenstiel
incision was developed to improve donor outcome after a kidney transplant. The aim of this study was to
investigate two methods of hand assistance and kidney removal during HALDN and their effect on the time it takes
for the donor to return to normal physical activity.
Methods/design: This study was initiated in November 2017 and is expected to last for 2 years. To be eligible for
the study, donors must be more than 20 years of age and must not be receiving permanent pain therapy. Only
donors with a single artery and vein in the graft are being enrolled in this trial. Donors with infections or scars in
the periumbilical or hypogastric area, bleeding disorders, chronic use of immunosuppressive agents, or active
infection will be excluded. Donors will be randomly allocated to either a control arm (periumbilical incision) or an
intervention arm (Pfannenstiel incision). The sample size was calculated as 26 organ donors in each group. The
primary endpoint is the number of days it takes the donor to return to normal physical activity (up to 4 weeks after
the operation). Secondary endpoints are intraoperative outcomes, including estimated blood loss, warm ischemia
time, and duration of the operation. Postoperative pain will be assessed using the visual analog scale, rescue
analgesic use, and peak expiratory flow rate. Length of hospital stay, physical activity score, time to return to work,
donor satisfaction, cosmetic score, postoperative complications, and all-cause mortality in living donors will also be
reported. Delayed graft function, primary non-function, serum creatinine levels, and glomerular filtration rate will
also be assessed in the recipients after transplantation.
Discussion: This is the first randomized controlled trial to compare the time it takes the living donor to return to
normal physical activity after HALDN using two different types of incision. The comprehensive findings of this study
will help decide which nephrectomy procedure is best for living donors with regard to patient comfort and
satisfaction as well as graft function in the recipient after transplantation.
Trial registration: ClinicalTrials.gov, NCT03317184. Registered on 23 October 2017.
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Background
Despite remarkable improvements in kidney procure-
ment from deceased donors, the demand for organs is
still higher than the number of available kidneys. The
use of living donor kidney transplantation (LDKT) has
been increased in an attempt to overcome the organ
shortage [1–4]. The main concern of LDKT is that a
healthy person undergoes major surgery to supply an
organ, which may have serious adverse effects. There-
fore, a safe nephrectomy method with a low complica-
tion rate is just as important as ensuring good graft
quality after transplantation [3, 5].
Open donor nephrectomy was the most common tech-
nique for kidney removal before laparoscopic surgery was
developed [6, 7]. Laparoscopic nephrectomy has obvious
intraoperative and postoperative advantages over open sur-
gery in terms of blood loss, postoperative pain, duration of
hospital stay, and convalescence [8–10]. In 1998, shortly
after the development of commercial ports, Wolf et al. [11]
reported the hand-assisted laparoscopic living donor neph-
rectomy (HALDN) technique. Since then, this technique
has been widely adopted [12]. HALDN offers better manual
control of bleeding, a shorter learning curve, less kidney
traction, faster kidney extraction, and shorter warm ische-
mia times [7, 11–13]. Nowadays, HALDN is one of the
most commonly applied surgical procedures, and it has a
relatively low complication rate [13].
HALDN is usually performed using a periumbilical or
Pfannenstiel incision for hand-port placement and kid-
ney extraction [14]. So far, several retrospective and
non-randomized prospective studies have compared peri-
umbilical and Pfannenstiel incisions [13, 15–18]. While
some studies have shown better donor outcomes for peri-
umbilical incision with regard to blood loss, warm ischemia
time, duration of the surgery, and postoperative pain
[15, 17, 18], Pfannenstiel incision is associated with fewer
early and long-term wound complications and better cos-
metic outcomes [13, 16]. Donors were also able to return to
work more quickly after a Pfannenstiel incision [15]. How-
ever, these conclusions were the results of retrospective or
non-randomized prospective studies. To our knowledge, the
use of these two different incisions during HALDN has not
been compared in a randomized controlled trial (RCT).
In this RCT, we are investigating the effect of two dif-
ferent hand-assistance and kidney removal techniques
during HALDN, using periumbilical and Pfannenstiel in-
cisions, on the time it takes for donors to return to nor-
mal physical activity. We will also analyze graft function
in the recipient after transplantation.
Methods/design
Setting
This is a single-center, expert-based RCT. The trial is now
underway at the Division of Transplantation Surgery,
Department of General, Visceral, and Transplantation Sur-
gery, University of Heidelberg. It was initiated in November
2017, and it is expected to progress for 2 years. The trial
was registered at ClinicalTrials.gov under registration num-
ber NCT03317184 on October 23, 2017. The Standard
Protocol Items: Recommendations for Interventional Trials
(SPIRIT) checklist is provided in Additional file 1.
Patient recruitment
The study protocol was accepted by the independent
Ethics Committee of the University of Heidelberg (regis-
tration number S-291/2017). As shown in the study flow
chart (Fig. 1), all kidney donors (including left and right
kidneys) are currently being screened for eligibility cri-
teria. To be eligible for the study, living donors must be
more than 20 years of age and must not be receiving
permanent pain therapy. Only donors with a single ar-
tery and vein in the graft are being enrolled in this trial.
Donors with infections or scars in the periumbilical or
hypogastric area, bleeding disorders, chronic use of im-
munosuppressive agents, and active infection are being
excluded. All included donors will be informed about peri-
umbilical and Pfannenstiel incisions for HALDN, as well
as their potential benefits and side effects. Eligible donors
will receive a written informed consent form. Donors who
sign the informed consent form will be included in the
study. Reasons for exclusion from the Hand-Assisted
laparoscopic donor nephrectomy PERiumbilical versus
Pfannenstiel incision and return to normal physical AC-
Tivity (HAPERPACT) trial will be documented and ex-
plained in the screening form. After baseline assessments
and assessment of eligibility, the patient will be random-
ized to the periumbilical or Pfannenstiel arm.
Outcome measures
During the HAPERPACT trial, donors will be monitored
before surgery, intraoperatively, on postoperative days
(PODs) 1, 2, 3, and at discharge. After discharge, patients
will be visited during postoperative weeks (POWs) 2, 4, and
8. During the first four POWs, donors will complete a
self-administered questionnaire every day. Demographic
and baseline clinical data, intraoperative findings, and post-
operative results will be recorded (Fig. 2). Furthermore,
graft function will be assessed until the fourth POW.
To enhance participant retention and to avoid loss to
follow-up, we call the patients during the follow-up period
to remind them of scheduled visits and to arrange ap-
pointments. When a patient is not able to participate in a
follow-up visit, we will speak with the patient on the tele-
phone and ask him/her to send us a photo of the incision.
Primary endpoint
Patients will complete the Katz Basic Activities of Daily
Living (ADL) self-maintenance questionnaire each day
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during the first four POWs until all normal activities are
recovered. This questionnaire indicates their ability to
perform daily living activities [19]. The Katz ADL evaluates
the patient’s independent performance in six functions:
bathing, dressing, using the toilet, transferring, continence,
and feeding. These functions are evaluated with yes/no
questions. A score of 6 indicates independence in all
six functions, demonstrating normal physical activity.
Since all donors are able to perform these basic activities
before the operation, the Katz ADL questionnaires are not
administered prior to surgery. The questionnaires will be
gathered at each follow-up visit, and the number of days it
takes to return to normal physical activity will be deter-
mined based on the answers. The primary endpoint has
been defined as the number of days from surgery until re-
turn to normal physical activity.
Secondary endpoints
Intraoperative outcomes, including estimated blood loss,
warm ischemia time, and operating time, will be reported.
Fig. 1 Study design flow chart. *Preoperative assessments including date of birth, gender, weight (kg), height (cm), and American Society of
Anesthesiologists score. **Return to normal physical activity will be self-assessed using the Katz Basic Activities of Daily Living self-maintenance
questionnaire during the first 4 postoperative weeks until all normal activities are recovered. PEFR peak expiratory flow rate, PNF primary
non-function, DGF delayed graft function, GFR glomerular filtration rate, IPAQ-SF International Physical Activity Questionnaire-Short Form
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Fig. 2 HAPERPACT trial design according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist
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In addition to the Katz ADL questionnaire, a physical ac-
tivity score will be determined using the International
Physical Activity Questionnaire-Short Form (IPAQ-SF).
The IPAQ-SF score will be calculated before the operation
and at POWs 2, 4, and 8. Postoperative pain will be
assessed using the visual analog scale (VAS 0–10, 0 = no
pain and 10 = unbearable distress) and by measuring
in-hospital rescue analgesics until discharge. The peak ex-
piratory flow rate (PEFR) will also be evaluated preopera-
tively and until discharge as an objective surrogate
measure of pain. Length of hospital stay, time to return to
work, postoperative complications, and all-cause mortality
will also be reported in living donors. The appearance of
incision scars will be evaluated with a patient satisfaction
score (Likert scale 1–5, with 5 indicating strongly satisfied
and 1 indicating strongly unsatisfied) and a cosmetic score
(defined by the Stony Brook Scar Evaluation Scale [20])
during the first eight POWs. Possible incisional hernia at
the site of the surgical incision will be examined by
palpation and ultrasonography during each visit. The
quality of the procured graft will also be evaluated in
recipients after both procedures. Delayed graft function,
primary non-function, serum creatinine levels, and glom-
erular filtration rates will be assessed in recipients until
POW 4. Secondary outcome measures are defined in
Table 1.
Standardized therapy and trial interventions
The site of hand-port placement will be randomized. All
other intraoperative and perioperative treatments are
standardized procedures. Prophylactic antibiotic therapy
and use of intravenous or oral analgesic agents to relieve
postoperative pain will be administered according to our
kidney transplantation manual [21].
According to the randomization arm, hand-port place-
ment and hand insertion will be via a midline periumbi-
lical or Pfannenstiel incision. HALDN with a
periumbilical incision will be performed by positioning
the donor in a left/right lateral decubitus position. A
5-mm laparoscope port will be placed at the midclavicu-
lar line in the left/right upper quadrant (two finger
breadths below the costal margin), and one working in-
strument (12 mm) will be placed at the level of the um-
bilicus to the left/right of the midline. HALDN with a
Table 1 Secondary endpoints of the HAPERPACT trial
Secondary endpoints Definitions
Warm ischemia time From the time of clamping the first renal artery in situ to flushing the kidney with chilled solution on
the back table (minutes)
Intraoperative complications Any complication occurring during the operation
Estimated blood loss The entire blood loss from skin incision to skin closure (milliliters)
Operating time From the time of skin incision to closure of the skin incision (minutes)
Postoperative pain Severity of pain measured by the 11-point visual analog scale (0 = no pain and 10 = unbearable distress)
Rescue analgesic Total amount of analgesics required during the first three postoperative days
Peak expiratory flow rate (PEFR) Maximum speed of expiration, measured with a peak flow meter
Postoperative complications Postoperative surgical complications (i.e., burst abdomen and hernia, wound infection, seroma, and hematoma,
intra-abdominal bleeding/hematoma, intra-abdominal abscess or collection, lymphocele, and postoperative ileus)
and medical complications (pneumonia, pleural effusion, urinary tract infection). Each complication will be graded
according to the Clavien-Dindo classification [29]
Length of hospital stay From the day of the operation until the day of discharge (days)
Time to return to work The number of days from discharge to return to work
IPAQ-SF score* The physical activity of patients will be evaluated preoperatively, and on postoperative weeks 1, 2, 4, and 8 using
the IPAQ-SF [18]
Patient satisfaction score Patient satisfaction score measured by the 5-point Likert scale (5 = strongly satisfied and 1 = strongly unsatisfied)
Cosmetic score Cosmetic score as defined by the Stony Brook Scar Evaluation Scale [20]
Incisional hernia Fascia or muscle defect (bulging hernial sac and palpable fascia gap) at the site of the surgical incision examined
by palpation and ultrasonography
Mortality Death due to any cause at any time during the follow-up period
Primary non-function (PNF) The graft never functions
Delayed graft function (DGF) The need for one or more hemodialysis treatments following transplantation prior to the onset of graft function.
The duration of DGF will be calculated from the date of transplantation to the date of the last dialysis treatment
Recipient serum creatinine level Serum creatinine level (mg/dL)
Glomerular filtration rate (GFR) GFR (mL/min/1.73 m2) calculated as 175 × (Scr)
–1.154 × (Age)–0.203 × (0.742 if female)
*IPAQ-SF International Physical Activity Questionnaire-Short Form
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Pfannenstiel incision will be performed by placing the
donor in the French position. A four-port transperito-
neal approach will be used: a 10-mm umbilical trocar for
the laparoscope, one 5-mm port in the midline, one
12-mm port at the level of the umbilicus to the left/right of
the midline, and an additional 5-mm port will be inserted
at the left/right border of the Pfannenstiel incision. As soon
as the blood vessels are divided and the nephrectomy is
completed, the graft will be extracted using the hand port.
At the end of the operation, an abdominal drain will be
placed and the wound will be closed.
Modification of the protocol
Protocol amendments will be considered by the principal
investigator after feedback from the Clinical Trial Center.
All protocol amendments will be submitted to the Ethics
Committee for approval. No further recruitments will take
place until the modifications are accepted.
Assessment of safety and termination criteria
To assess the safety of the periumbilical and Pfannenstiel
approaches, serious adverse events (SAEs) will be ob-
served and evaluated. Only intervention-related events
that occur during surgery and follow-up will be docu-
mented. At each visit, the physician will ask the donor if
he/she has suffered from any SAEs since the last visit. The
attending physician must tell the principal investigator about
any reported SAEs within 24 h. The report will be complete
and include details of the SAE and whether the SAE was
caused by the trial treatment. All intervention-related SAEs
will be documented and analyzed.
Donors will be excluded from the study if they with-
draw their consent to participate in the trial. A donor
may withdraw consent at any time without explanation
and without affecting further medical care. The principal
investigator may terminate the trial at any time in
consultation with the key research associates and the
biostatistician. Possible reasons for termination include
high morbidity or mortality rates and any indication of
potential health hazards caused by either the study treat-
ment or external factors.
Randomization and blinding
Donors will be randomized to the different groups using
the block randomization method. Each block contains
two groups of periumbilical and Pfannenstiel incisions.
The block size is hidden from the trial executers and cli-
nicians. Possible balanced combinations of these groups
within the block are numbered consecutively. Then,
blocks are randomly chosen using simple randomization
software (Microsoft Excel®), and a series of randomly
assigned periumbilical and Pfannenstiel incisions are gener-
ated based on the random sequence of blocks. Allocation
will be concealed using sequentially numbered, sealed
opaque envelopes prepared by a member of our Clinical
Trial Center. Donors will be randomly allocated to either
the control arm (periumbilical incision, Group A), or the
intervention arm (Pfannenstiel incision, Group B) a day be-
fore surgery. The trial executors receive randomly gener-
ated treatment allocations within sealed opaque envelopes.
Afterwards, medical staff will personally inform the expert
surgeon as to which treatment group the patient has been
randomized. To avoid any potential prediction of group al-
location, information on the block length will be kept away
from the study site.
After the operation, the periumbilical and hypogastric
regions will be covered with a double wound dressing
until discharge. During this period, the severity of pain,
rescue analgesic, and PEFR will be evaluated by anesthe-
siologists blinded to the incision type. Participants will
also be blinded to the incision type. If blinding could
affect the patient’s treatment, for example in the case of
a medical emergency or serious medical condition, then
the participant/assessor will be unblinded. After POD 4,
a nephrologist who is unaware of the study will evaluate
and document the primary and secondary endpoints of
the trial. At the end of the trial, the data management
center will receive all sealed envelopes and will check
the accuracy of randomization numbers.
Data management
All data will be collected and recorded in case report
forms (CRFs) by an investigator before transfer to the
data management center. To ensure accurate data col-
lection, after each patient has been visited, the CRF will
be completed by an investigator who did not evaluate
the patient. All demographic and baseline clinical data,
as well as primary and secondary outcome measures,
will be recorded in the CRF. All data will be checked,
and any missing data will be obtained from the trial
database or from participants. To ensure patient confi-
dentiality, the CRF for each patient will be given an an-
onymous allocation number. We will obtain permission
to continue follow-up and data collection in the event of
withdrawal from the study. The responsible investigator
must review and sign all completed CRFs. Afterwards,
data will be statistically analyzed by a statistician who is
unaware of the allocated treatment.
Statistical methods
Sample size
The null hypothesis is that Pfannenstiel incision is not
superior to periumbilical incision in terms of the average
number of days it takes the donor to return to normal
physical activity in the 4 weeks after surgery. We chose
10 days difference in return to normal physical activity
as the minimal clinically important difference, because a
difference of less than 10 days is not valuable enough to
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decide the standard surgical method. Therefore, we used
a difference of 10 days for sample size calculation. The
standard deviation is expected to be 13 days, according
to the results of El-Galley et al. [15], who compared days
to return to work between periumbilical and Pfannen-
stiel incision groups. However, we chose “days to return
to normal physical activity” as the primary endpoint ra-
ther than “days to return to work” because the nature of
patients’ work and their capabilities are different, and
some of our living donors may be unemployed or house-
keepers. A one-sided significance level of α = 0.05, a
power of 80%, and a sample size of 44 patients (22 per
group) are required to apply a two-sample t test (calcula-
tions performed with AddPlan 6.0). To account for a
15% drop-out rate, 26 patients will be enrolled in each
study arm (52 patients in total).
Statistical analysis
The primary endpoint is the number of days from sur-
gery to return to normal physical activity. This will be
assessed using the Katz ADL questionnaire. The primary
analysis will test the following hypotheses:
H0 μPfannenstiel ≥ μPeriumbilical
H1 μPfannenstiel < μPeriumbilical,
where μPfannenstiel and μPeriumbilical are the mean number
of days in the respective intervention groups. The pri-
mary endpoint will be compared between the interven-
tion groups using a Student’s t test and a one-sided
significance level of 5%. Additionally, a Mann-Whitney U
test will be performed for sensitivity analysis. According to
the intention-to-treat approach, all patients will be ana-
lyzed in the group to which they were randomized.
All secondary outcomes will be analyzed using appro-
priate summary measures depending on the distribution of
the data and descriptive p values. Categorical data will be
presented as absolute and relative frequencies. Continuous
data will be presented as mean values with standard devia-
tions and by median values with interquartile ranges, mini-
mum values, and maximum values. Statistical analysis will
be performed using SPSS version 24.0 (SPSS, Inc., Chicago,
IL, USA). A statistical analysis plan will be developed by the
principal investigator by the end of recruitment.
Discussion
LDKT is one of the best solutions for organ shortage.
Since living kidney donors give others a second chance
to live, it is very important that they undergo the safest
possible surgical procedure with the lowest risk and
complication rate. Although both HALDN procedures
(periumbilical and Pfannenstiel) are accepted surgical ap-
proaches [22–25], these two different incision methods
have not been compared in an RCT. This RCT was
initiated to compare the outcome of periumbilical and
Pfannenstiel incisions.
Only one RCT has compared HALDN using a perium-
bilical incision with pure laparoscopic donor nephrec-
tomy using a Pfannenstiel incision for graft extraction
[26]. The authors compared operation time, warm ische-
mia time, complications, and quality of life between the
two groups, but they did not report the time it took for
the donor to return to work/normal physical activity or
wound appearance. This RCT also compared two different
methods (pure laparoscopy versus HALDN) as well as
two types of incision. There are also some published
non-randomized or retrospective studies that compare
periumbilical and Pfannenstiel incisions for hand assist-
ance and/or kidney removal in HALDN or laparoscopic
donor nephrectomy [15–18]. However, although El-Galley
et al. [15] reported the time to return to normal activity
and work, none of these studies evaluated the donor’s
comfort and satisfaction; they mainly compared the occur-
rence of complications and length of hospital stay after
the two procedures.
The HAPERPACT trial will be the first RCT to evalu-
ate the impact of periumbilical and Pfannenstiel inci-
sions on donor recovery. We will compare the time it
takes for the donor to return to normal physical activity
after the two different procedures. This will indicate pa-
tient satisfaction and comfort, as well as the influence
on economy and burden of disease.
The secondary findings of this RCT will compare the
intraoperative and postoperative results in living kidney do-
nors. The HAPERPACT trial is novel in that it investigates
all factors associated with donor satisfaction after nephrec-
tomy, including postoperative pain, rescue analgesics,
PEFR, physical activity (using IPAQ), length of hospital stay,
time to return to work, patient satisfaction, and cosmetic
score. To ensure that our findings are more encyclopedic,
the quality of the transplanted graft and graft function in
recipients will also be monitored in this trial.
One limitation of this RCT is that the primary end-
point cannot be evaluated blind. However, some early
outcome measures will be evaluated double blindly
(participant and assessor blinded) until discharge by cover-
ing both periumbilical and hypogastric areas using double
wound dressing. Furthermore, to prevent bias in further as-
sessments, all follow-up visits will be performed by a neph-
rologist who is unaware of the study. Another limitation is
that the primary outcome of this RCT is a subjective,
self-maintenance measure. However, results of the Katz
ADL self-administered questionnaire are known to be valid
and reliable [27]. In addition to the Katz ADL question-
naire, we will also use the established IPAQ-SF [28], which
will be completed by the investigator before and after sur-
gery. There is no data monitoring process in the HAPER-
PACT trial, because the methods used are both standard
surgical procedures for living donor nephrectomy and also
because the biggest part of documentation in this trial is
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the standard clinical follow-up of the patients. Therefore, a
data monitoring committee is dispensable in this trial.
In summary, published retrospective and non-randomized
prospective studies have not clarified the advantages
and disadvantages of periumbilical versus Pfannenstiel
incisions in HALDN. The HAPERPACT trial will be the
first RCT to compare the outcome of HALDN using two
different types of incision. The comprehensive findings of
this study may help to decide the optimal nephrectomy
procedure for earlier return to normal physical activity,
comfort, and satisfaction in donors as well as graft func-
tion in recipients.
Trial status
The HAPERPACT trial is currently recruiting participants.
Additional file
Additional file 1: SPIRIT checklist. (DOC 123 kb)
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